Could a common diabetes pill prevent heart failure after a heart attack?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years; * STEMI (e.g., ST elevation above the J-point of ≥0.1 millivolt in ≥two contiguous leads or left bundle branch block) or very high-risk NSTEMI (e.g., dynamic ECG changes or ongoing chest pain or acute heart failure or hemodynamic instability independent of ECG changes or life-threatening ventricular arrhythmias) with LV dysfunction (LVEF ≤45%); after completion of PCI or angiography procedure * eGFR ≥ 25 mL/Min per 1.73m²; * Systolic blood pressure (SBP) before first dosing \>100 mmHg and/or Diastolic blood pressure (DBP) \>70 mmHg before first dosing; * Ability to provide written informed consent and willing to participate in the 6-month follow-up period. * Affiliation to a national health care system (AME are not allowed). Exclusion Criteria: * Cardiogenic shock (SBP \<90 mmHg with clinical signs of low output or patients requiring inotropic agents) at randomization; * Referred to surgery for coronary artery bypass grafting (CABG) or treatment of acute complications (e.g. ventricular septal rupture); * Any other form of diabetes than diabetes type 2 * History of diabetic ketoacidosis (DKA); Known contra-indication to SGLT-2 inhibitors (hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption); * \>1 episode of severe hypoglycemia within the last 6 months under treatment with insulin or sulfonylurea; * Acute symptomatic urinary tract infection (UTI) or genital infection at the time of randomization; * Concomitant treatment (and/or within the 4 weeks prior to the baseline visit) with any SGLT-2 inhibitor (dapagliflozin, canagliflozin, empagliflozin) * Echocardiographic examination of insufficient quality to permit adequate analysis of the study end-points. * Impossibility to evaluate cardiac remodeling using TTE (e.g., pacemaker or defibrillator …); * Atrial fibrillation rhythm at randomization; * Life expectancy \<6 month; * Known pregnancy at time of randomization; * Breastfeeding women * Females of childbearing potential without adequate contraceptive methods (i.e. sterilization, intrauterine device, vasectomized partner; or medical history of hysterectomy) * Current participation in another interventional trial. Patients under guardianship or curatorship